Find a study
Browse recruiting studies near you — free to check, always your choice.
55 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Heart / cardiovascular diseaseKidney disease
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Testing whether orforglipron changes heart outcomes in adults with heart disease and/or kidney
📍 Instituto de Investigaciones Clínicas Bahia Blanca · Bahía Blanca, · Get directions →
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
- Dementia / Alzheimer's
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Testing the safety and effects of two drugs for agitation in Alzheimer’s dementia
📍 Esperanza Clinical · Murrieta, CA · +8 more US sites · Get directions →
The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.
- Parkinson's disease
A Study of Buntanetap in Participants With PD
Testing the long-term safety of buntanetap in people with Parkinson’s
📍 University of Alabama at Birmingham · Birmingham, AL · +26 more US sites · Get directions →
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study.
- Parkinson's disease
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
Testing a Parkinson’s surgery approach to see if it is safe and works
📍 Banner Sun Health Research Institute · Sun City, AZ · +32 more US sites · Get directions →
Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).
- Parkinson's disease
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
Testing a carbidopa and levodopa extended-release capsule in people with Parkinson’s
📍 Barrow Neurological Institute · Phoenix, AZ · +26 more US sites · Get directions →
The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).
- Dementia / Alzheimer's
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Testing whether KarXT plus KarX-EC is safe and works for memory problems in Alzheimer’s disease
📍 Healthy Brain Clinic · Long Beach, CA · +27 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Dementia / Alzheimer's
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Testing long-term safety and effectiveness of two medicines for agitation in Alzheimer’s dementia
📍 Local Institution - 2609 · Chandler, AZ · +39 more US sites · Get directions →
The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.
- Dementia / Alzheimer's
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
Studying whether ovarian hormones are linked to aging and Alzheimer’s risk in women
📍 Mayo Clinic · Jacksonville, FL · +1 more US site · Get directions →
The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.
- Dementia / Alzheimer's
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Testing whether yearly donanemab helps people with dementia after a prior study
📍 Banner Alzheimer's Institute · Phoenix, AZ · +39 more US sites · Get directions →
The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
- Heart / cardiovascular diseaseHigh blood pressure
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Testing a drug taken with empagliflozin in adults with type 2 diabetes and heart disease
📍 Pinnacle Research Group, LLC · Anniston, AL · +39 more US sites · Get directions →
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure.
- Dementia / Alzheimer's
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Testing a drug called trontinemab for early Alzheimer’s disease dementia
📍 Banner Alzheimer?s Institute · Phoenix, AZ · +32 more US sites · Get directions →
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
- Dementia / Alzheimer's
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Testing a treatment called KarXT plus KarX-EC for psychosis in people with Alzheimer's disease
📍 Gilbert Neurology Partners/CCT Research · Gilbert, AZ · +5 more US sites · Get directions →
The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
- Parkinson's disease
18F-DOPA II - PET Imaging Optimization
Testing an imaging scan to study Parkinson’s disease using PET
📍 WC Mackenzie Health Science Centre / University of Alberta Hospital · Edmonton, Alberta · Get directions →
A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism.
- Heart / cardiovascular diseaseKidney disease💵 May compensate
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
Testing whether sotagliflozin can slow kidney damage in type 1 diabetes
📍 Stanford University Medical Center · Stanford, CA · +12 more US sites · Get directions →
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D.
- DepressionDementia / Alzheimer's
Aβ Dynamics in LLMD
Testing how treating depression may change brain markers linked to Alzheimer’s
📍 NYU Langone Health · New York, NY · +1 more US site · Get directions →
This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers.
- Dementia / Alzheimer's
Epidemiology and Biomarker Study in Alzheimer's Disease
Studying how memory changes over time and blood test results in people with dementia
📍 Care Access - Houston · Houston, TX · Get directions →
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
- Parkinson's disease
Cortical Electrophysiology of Response Inhibition in Parkinson's Disease
Studying how deep brain stimulation in Parkinson’s affects brain control of stopping actions
📍 Emory University Hospital · Atlanta, GA · +1 more US site · Get directions →
Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that involve prefrontal cortex executive functions, and therefore have a direct impact on the patient's ability to inhibit actions.
- Dementia / Alzheimer's
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
Testing whether a brain PET scan can predict worsening memory problems
📍 Endeavor Health Systems · Evanston, IL · Get directions →
CMK-0301 is a multi-site, randomized clinical trial to evaluate the safety and efficacy of \[F-18\]Flornaptitril-PET (F-18 FNT-PET) for the prediction of clinical progression of Mild Cognitive Impairment (MCI) with either Suspected Chronic Traumatic Encephalopathy (CTE) or Alzheimer's Disease (AD). The primary objectives of the study are to: (1) To determine the accuracy of F-18 FNT-PET in prediction of clinical decline and (2) To assess the safety and tolerability of F-18 FNT.
- Dementia / Alzheimer's
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Testing a treatment (KarXT plus KarX-EC) for memory problems in Alzheimer’s dementia
📍 Fullerton Neurology and Headache Center · Fullerton, CA · +29 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Dementia / Alzheimer's
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
Comparing tau brain scan images in different types of dementia
📍 Perelman Center for Advance Medicine · Philadelphia, PA · Get directions →
The investigators will compare \[18F\]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal subjects.
- Dementia / Alzheimer's
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
Testing a drug combination to treat agitation in adults with Alzheimer’s
📍 Chandler Clinical Trials, LLC · Chandler, AZ · +39 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
- Obesity / overweightHeart / cardiovascular disease
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Testing whether maridebart cafraglutide lowers heart risks in people with heart disease and obesity
📍 Alliance For Multispecialty Research - Daphne · Daphne, AL · +39 more US sites · Get directions →
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
- Obesity / overweightHeart / cardiovascular disease💵 May compensate
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Testing maridebart cafraglutide with standard care to reduce heart failure events in obese people
📍 University of Alabama Saint Vincent's Birmingham · Birmingham, AL · +39 more US sites · Get directions →
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE).
- Obesity / overweightHeart / cardiovascular disease
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Testing how well NNC0487-0111 works versus placebo in heart failure with excess body weight
📍 Advanced Cardiovascular, LLC · Alexander City, AL · +39 more US sites · Get directions →
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight.
- Parkinson's disease
BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease
Testing a new long-acting levodopa dose to improve “on” time in Parkinson’s
📍 Cleveland Clinic · Cleveland, OH · Get directions →
The purpose of this study is to evaluate the effect of IPX203 (Crexont®) - the newest extended-release levodopa formulation - on the duration and quality of good on time, using a wearable device to monitor symptoms. 'Good on time' refers to a period (minutes to hours) when a patient experiences optimal symptom control due to effective medication and has better overall functioning without troublesome dyskinesias.
- Dementia / Alzheimer's
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
Testing the safety and side effects of Zunveyl in people with mild to moderate Alzheimer’s
📍 Tekton Research Saint Louis Psychiatry · St Louis, MO · Get directions →
The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.
- Heart / cardiovascular disease
COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes
Testing colchicine and plain aspirin, alone or together, for heart outcomes in high-risk type 2
📍 Curtin University · Bentley, Western Australia · Get directions →
To evaluate the efficacy and safety of colchicine and non-enteric coated aspirin, combined or alone, to improve cardiovascular outcomes in high-risk patients with type 2 diabetes.
- Dementia / Alzheimer's
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Testing trontinemab for safety and effectiveness in early Alzheimer’s disease dementia
📍 University of Alabama at Birmingham · Birmingham, AL · +34 more US sites · Get directions →
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
- Parkinson's disease
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Testing an IV drug in people with early-stage Parkinson’s disease
📍 University of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
- Dementia / Alzheimer's
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Screening people who may be eligible for Alzheimer’s disease studies for dementia
📍 University of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
- Dementia / Alzheimer's
Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial
Testing a sleep medicine for insomnia symptoms in a person with dementia
📍 Nova Scotia Health · Halifax, Nova Scotia · Get directions →
Insomnia is a highly common, chronic disorder that is distressful for the patient but also for caregivers and can give rise to a heavy burden on the healthcare team. Sleeping aids like benzodiazepines and other sedatives (e.g., zolpidem, zopiclone) have been widely used to help treat insomnia.
- Dementia / Alzheimer's
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Testing a medicine for psychosis in adults with moderate to severe Alzheimer’s
📍 Local Institution - 1227 · Chandler, AZ · +39 more US sites · Get directions →
The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.
- Dementia / Alzheimer's
Biomarker Exploration in Aging, Cognition and Neurodegeneration
Testing how MRI, PET scans, and memory tests can detect early dementia
📍 University of California, Irvine · Irvine, CA · Get directions →
The purpose of this research study is to understand the factors that underlie changes in thinking and memory with increasing age. The investigators will test the usefulness of MRI, PET, and cognitive testing in detecting subtle changes in the brain that precede cognitive decline.
- Parkinson's disease
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
Comparing treatments to see which works better for hallucinations in Parkinson’s disease
📍 Southern Arizona VA Health Care System, Tucson, AZ · Tucson, AZ · +23 more US sites · Get directions →
Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems. Many patients also have other symptoms not related to movement, called non-motor symptoms, which may affect one's mood or emotions, memory or thinking, or cause one to see or hear things that aren't real (hallucinations) or believe things that aren't true (delusions).
- Parkinson's disease
A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's
Testing a wearable sensor to track swallowing and drooling problems in people with Parkinson’s
📍 Northwestern University · Evanston, IL · Get directions →
The purpose of this study is the development and early-stage validation of a wearable sensor for dysphagia in patients with PD.
- Dementia / Alzheimer's
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Testing a potential Alzheimer disease treatment in people with early AD genetic risk
📍 University of Alabama in Birmingham · Birmingham, AL · +10 more US sites · Get directions →
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remternetug.
- Dementia / Alzheimer's
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
Testing a medicine called masupirdine versus placebo for agitation in Alzheimer’s dementia
📍 Advanced Research Center, Inc. · Anaheim, CA · +26 more US sites · Get directions →
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
- Heart / cardiovascular disease💵 May compensate
Canagliflozin Targeting Vascular Inflammation
Testing canagliflozin to reduce blood vessel inflammation in cardiovascular disease
📍 University of Ottawa Heart Institute · Ottawa, Ontario · Get directions →
CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs.
- Heart / cardiovascular disease
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Testing a medicine to see its cardiovascular effects in adults on dialysis
📍 Nephrology of North Alabama · Decatur, AL · +39 more US sites · Get directions →
This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.
- Dementia / Alzheimer'sParkinson's disease
Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia
Studying how nerve cell loss affects thinking ups and downs in Lewy body dementia
📍 Virginia Commonwealth University · Richmond, VA · Get directions →
The proposed study aims to address the critical gaps in understanding the mechanisms of CF (Cognitive Fluctuations) by leveraging recently emerged molecular biomarkers, advanced neuroimaging techniques to assess measures of cholinergic degeneration, and synchronous EEG and assessments of attention. One of the overarching innovations of study is combining all of these assessments into one integrated research plan
- Obesity / overweightType 2 diabetesHeart / cardiovascular disease
Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants
Testing the diabetes medicine pioglitazone in people with type 2 diabetes, obesity, and heart
📍 Texas Diabetes Institute/UH · San Antonio, TX · Get directions →
Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1.
- Parkinson's disease
Personalized Real-Time DBS and PD Mechanisms
Studying how closed-loop deep brain stimulation and levodopa affect Parkinson’s motor symptoms
📍 Cleveland Clinic · Cleveland, OH · Get directions →
A prospective cohort of patients scheduled to undergo deep brain stimulation (DBS) implantation surgery for the treatment of Parkinson's disease as per standard of care will be invited to participate in this study. This mechanistic study is aimed at better understanding the role of basal ganglia beta band (11-35 Hz) oscillations and resonance in the manifestation of Parkinson's disease (PD) motor signs using closed-loop electrical neurostimulation, levodopa medication, and computational modeling.
- Dementia / Alzheimer's
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
Studying nighttime agitation and restless legs in people with Alzheimer’s
📍 The University of Texas at Austin · Austin, TX · Get directions →
Nighttime agitation in persons with Alzheimer's disease causes patient suffering, distresses caregivers, and often results in prescriptions for harmful antipsychotics. Effective treatments are lacking because of limited knowledge of the etiology of nighttime agitation.
- Dementia / Alzheimer's
Preventing Alzheimer's With Cognitive Training
Testing whether cognitive training can help prevent Alzheimer’s disease
📍 University of Florida · Gainesville, FL · +6 more US sites · Get directions →
Dementia is the most expensive medical condition in the US and increases in prevalence with age. More than 5 million Americans have Alzheimer's disease, the most common form of dementia.
- Heart / cardiovascular diseaseDementia / Alzheimer's
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Testing whether lowering cholesterol in older adults affects heart and memory outcomes
📍 University of Alabama at Birmingham · Birmingham, AL · +37 more US sites · Get directions →
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo.
- Dementia / Alzheimer's
[18F]PI-2620 Phase 3 Histopathological Study
Testing a PET brain scan to detect tau buildup in Alzheimer’s
📍 Barrow Neurological Institute · Phoenix, AZ · +22 more US sites · Get directions →
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with \[18F\]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.
- Dementia / Alzheimer's
Nabilone for Agitation Blinded Intervention Trial
Testing nabilone as a treatment for agitation in people with Alzheimer’s dementia
📍 University of Calgary · Calgary, Alberta · Get directions →
This study will look at whether nabilone is an effective treatment for agitation in Alzheimer's disease (AD) patients. Agitation is highly prevalent in patients with AD and is one of the most distressing and challenging-to-treat symptoms.
- Heart / cardiovascular diseaseDepression
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
Testing home-based telehealth therapy to improve daily functioning in people with heart disease and
📍 Ralph H. Johnson VA Medical Center, Charleston, SC · Charleston, SC · Get directions →
The purpose of this study is to demonstrate whether Behavioral Activation for depression delivered via home based telehealth (BA-HT) is effective in improving social and role functioning in Veterans recently discharged from Cardiovascular disease (CVD-related) inpatient care. Eligible participants will receive either (1) twelve sessions of BA-HT or (2) standard best practices post CVD hospitalization care.
- Obesity / overweightHeart / cardiovascular diseaseHigh blood pressure
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
Testing timing of blood pressure medicines in people with obesity and high blood pressure
📍 University of Alabama at Birmingham · Birmingham, AL · Get directions →
Obese individuals have a higher prevalence of nocturnal hypertension and non-dipping blood pressure (BP). These conditions are associated with an increased risk of cardiovascular (CV) events and death.
- Parkinson's disease
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
Measuring serotonin 2A brain receptor activity in people with Parkinson’s
📍 Vanderbilt University Medical Center · Nashville, TN · Get directions →
It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.
- Dementia / Alzheimer's
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Testing drugs to see how they affect brain changes in people with a genetic form of early
📍 University of Alabama in Birmingham · Birmingham, AL · +10 more US sites · Get directions →
The purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amyloid beta (Aβ) pathological disease accumulation demonstrated by Aβ positron emission tomography (PET) imaging.
- Dementia / Alzheimer'sParkinson's disease
Comparing Antipsychotic Medications in LBD Over Time
Comparing medicines to see which works better for hallucinations or delusions in Lewy body disease
📍 University Health System · San Antonio, TX · +1 more US site · Get directions →
The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).
- Type 2 diabetesHeart / cardiovascular disease
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
Testing tirzepatide to see if it slows plaque buildup in heart arteries in people with type 2
📍 Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute) · Torrance, CA · Get directions →
A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.
- Parkinson's disease
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Testing BHV-8000 for safety and effectiveness in adults with early Parkinson's disease
📍 Site-049 · Birmingham, AL · +14 more US sites · Get directions →
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.
- Dementia / Alzheimer's
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Testing a treatment for agitation in adults with Alzheimer’s disease
📍 Imaging Endpoints · Scottsdale, AZ · +38 more US sites · Get directions →
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.